An Open-label, Multicenter, Phase 1/1b Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, or Obinutuzumab, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Profile

An Open-label, Multicenter, Phase 1/1b Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, or Obinutuzumab, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs DCDS 0780A (Primary) ; Obinutuzumab; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 30 Sep 2019 to 4 Sep 2019.
    • 24 Oct 2017 Planned primary completion date changed from 30 Sep 2019 to 4 Sep 2019.
    • 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top